ArticleJournal of cachexia, sarcopenia and muscle2021
Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease.
Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatology international · 2025Guideline
- The Liver-Bone Axis in Steatotic Liver Disease.Calcified tissue international · 2026Review
- Association between low skeletal muscle mass assessed by deep learning-based CT and MASLD: a prospective cohort study.Diabetology & metabolic syndrome · 2026Article
- Serum 25(OH)D3 and advanced liver fibrosis in type 2 diabetes: a Chinese hospital cohort with NHANES validation and mortality follow-up.Frontiers in nutrition · 2026Article
- Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction-associated steatotic liver disease.Frontiers in epidemiology · 2026Article
- Association between the ratio of uric acid to high-density lipoprotein cholesterol (UHR) and the abnormal risk of sarcopenia: Evidence from two large population-based surveys and interpretable machine learning-driven sarcopenia screening.Therapeutic advances in endocrinology and metabolism · 2026Article
- Novel subtypes of metabolic associated steatotic liver disease linked to clinical outcomes: implications for precision medicine.Journal of translational medicine · 2025Article
- Review of roles of RNA-binding proteins on NAFLD and the related pharmaceutical measures.Biomolecules & biomedicine · 2025Review
- Serum calcium levels and the risk of sarcopenia in young adults: insights from NHANES 2011-2018.Frontiers in nutrition · 2025Article
- Comment on 'Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank' by T. S. Lim et al.-Authors' Reply.Journal of cachexia, sarcopenia and muscle · 2025Article
- Higher risk of carotid plaque among lean individuals with non-alcoholic fatty liver disease: A retrospective study.PloS one · 2025Article
- Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on "Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis".Clinical and molecular hepatology · 2024Article
- Metabolic dysfunction associated fatty liver disease in healthy weight individuals.Hepatology international · 2024Review
- MAFLD as part of systemic metabolic dysregulation.Hepatology international · 2024Review
- Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography.Journal of cachexia, sarcopenia and muscle · 2024Article
- Article
- The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.BMC gastroenterology · 2024Article
- Metabolic-associated fatty liver disease and sarcopenia: A double whammy.World journal of hepatology · 2024Review
- Association of low muscle mass and obesity with increased all-cause and cardiovascular disease mortality in US adults.Journal of cachexia, sarcopenia and muscle · 2024Article
- Institutional Nomogram for Estimating Risk of Metabolic Associated Fatty Liver Disease (MAFLD).Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia is a significant indicator of the severity of non-alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk of liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) among subjects with metabolic dysfunction-associated fatty liver disease (MAFLD).
methodsSubjects from the Korea National Health and Nutrition Examination Survey 2008-2011 were selected (n = 8361). Sarcopenia was defined using the sarcopenia index. Hepatic steatosis was defined as a fatty liver index ≥30. Significant liver fibrosis was defined as a fibrosis-4 index (FIB-4) ≥2.67 or the highest quartile of non-alcoholic fatty liver disease fibrosis score (NFS). High probability of ASCVD was defined as ASCVD risk score >10%.
resultsThe mean age was 48.5 ± 15.6 years, and 42.6% of subjects were male. The prevalence of MAFLD was 37.3% (n = 3116 of 8361), and the proportion of sarcopenic subjects was 9.9% among those with MAFLD. After adjusting for confounders, the risk of significant liver fibrosis significantly increased from non-sarcopenic subjects with MAFLD [odds ratio (OR) = 1.57 by FIB-4 and 2.13 by NFS] to sarcopenic subjects with MAFLD (OR = 4.51 by FIB-4 and 5.72 by NFS), compared with subjects without MAFLD (all P < 0.001). The risk for high probability of ASCVD significantly increased from non-sarcopenic subjects with MAFLD (OR = 1.47) to sarcopenic subjects with MAFLD (OR = 4.08), compared with subjects without MAFLD (all P < 0.001).
conclusionsThe risks of significant liver fibrosis and ASCVD differed significantly according to sarcopenic status among subjects with MAFLD. An assessment of sarcopenia might be helpful in risk stratification among subjects with MAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.